MarketPeel
Insider Trading Intelligence
RM

Richard A. Md Miller

BOLT
DIRECTOR · BOLT BIOTHERAPEUTICS, INC. · CIK 0001031847
FILING MIX · LIFETIME94%/6%
BUYS
33
SELLS
2
TOTAL VALUE
$3.67M
COMPANIES
2
ACTIVE SINCE
Dec 2020
HOLDINGS NOW
1,218,103
AVG SELL PX
TRADE KIND
SHOWING 35 / 35
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
19 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Richard A. Md Miller, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d19+68.42%+4.27%-1.70%+5.97%+6.05%
14d19+68.42%+7.27%-2.15%+9.41%+8.29%
30d19+68.42%+15.70%-1.54%+17.24%+10.47%
60d19+36.84%+2.33%+1.88%+0.45%-9.56%
90d19+36.84%-3.46%-2.63%-0.83%-6.64%
180d19+31.58%+63.29%+2.33%+60.95%-6.54%
1y19+68.42%+71.93%+8.10%+63.82%+74.89%
2y19+89.47%+318.94%+35.30%+283.64%+88.23%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BOLT · 25,000 shares · as of Jun 12, 2023
06,25012,50018,75025,0002023SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 33 buys / 2 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
5,000$12.05$60.3K1,193,103May 18, 2026May 20, 2026View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
1,932$12.01$23.2K1,195,035May 18, 2026May 20, 2026View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,000,0001,000,000Dec 4, 2025Dec 8, 2025View →
CRVS
CORVUS PHARMACEUTICALS, INC.
SALE
President and CEO
559,0730May 7, 2025May 9, 2025View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
559,073$3.50$1.96M1,136,707May 7, 2025May 9, 2025View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
750,000750,000Dec 20, 2024Dec 20, 2024View →
CRVS
CORVUS PHARMACEUTICALS, INC.
SALEGRANT
Gift
302,0161,188,103May 10, 2024May 14, 2024View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
559,073559,073May 6, 2024May 7, 2024View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
577,634$1.73$1000.0K577,634May 6, 2024May 7, 2024View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
500,000500,000Dec 6, 2023Dec 8, 2023View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jun 12, 2023Jun 14, 2023View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
800,000800,000Mar 31, 2023Apr 3, 2023View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Dec 14, 2022Dec 16, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
10,000$0.78$7.8K1,490,119Dec 14, 2022Dec 15, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
50,000$0.74$37.0K1,480,119Dec 13, 2022Dec 15, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
25,000$0.76$19.1K1,394,405Sep 28, 2022Sep 28, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
5,000$0.82$4.1K1,369,405Sep 20, 2022Sep 20, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
2,700$0.82$2.2K1,364,405Sep 20, 2022Sep 20, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
12,300$0.81$10.0K1,361,705Sep 20, 2022Sep 20, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
320,000320,000Aug 11, 2022Aug 15, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
5,000$1.00$5.0K1,349,405Jun 27, 2022Jun 28, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
5,000$1.03$5.2K1,344,405Jun 24, 2022Jun 28, 2022View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jun 10, 2022Jun 10, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
890$1.01$8991,339,405Jun 6, 2022Jun 6, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
4,830$0.98$4.7K1,338,345Jun 2, 2022Jun 6, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
170$0.97$1651,338,515Jun 2, 2022Jun 6, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
15,000$1.64$24.5K1,333,515Mar 31, 2022Apr 1, 2022View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Mar 24, 2022Mar 28, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
5,000$1.59$8.0K1,318,515Mar 17, 2022Mar 17, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
25,000$1.47$36.6K1,313,515Mar 15, 2022Mar 17, 2022View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
320,000320,000Sep 9, 2021Sep 13, 2021View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
10,000$1.93$19.3K1,288,515Aug 20, 2021Aug 23, 2021View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
35,714$2.80$100.0K35,714May 4, 2021May 5, 2021View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASE
President and CEO
100,000$3.50$350.0K1,278,515Feb 17, 2021Feb 17, 2021View →
CRVS
CORVUS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
320,000320,000Dec 16, 2020Dec 17, 2020View →
Other insiders · BOLT
Loading peer insiders…
About this filer
CIK 0001031847
ROLE
Director
PRIMARY
BOLT
COMPANIES
2
ACTIVE SINCE
Dec 2020
MARKETPEEL · /INSIDER/0001031847DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback